Health
FDA Warns Indian Toothpaste Maker Over Long-Delisted Color Additive
The FDA has issued a warning letter to Pritam International Private Limited over a prohibited color additive and manufacturing violations at its Indian facility. Published Nov. 3, 2026, the letter follows a U.S. recall covering more than 4 million tube...
Nesta criticizes ministers over stalled healthy food standard
Nesta has accused UK ministers of failing to lead on the proposed healthy food standard, warning that delays to mandatory health reporting and sales targets threaten a major opportunity to reduce obesity. The organization, whose work underpins the poli...
FDA clears exaluren IND for U.S. participation in Eloxx's Phase 2 ADPKD trial
Eloxx Pharmaceuticals can begin opening U.S. sites for its global EXPRESS trial after the Food and Drug Administration cleared an Investigational New Drug application for exaluren, the company announced on October 29, 2026. The Phase 2 study will evalu...
Australia plans stricter sunscreen testing after SPF shortfalls
Sunscreen brands would have to submit test results for finished products before listing them under reforms announced Tuesday by Australia's Therapeutic Goods Administration. The proposals follow a consumer investigation that found 16 of 20 popular suns...
Mississippi AG Fitch Calls on National Security Council to Safeguard GLP-1 Drug Supply Chain from Chinese Exploitation
Attorney General Lynn Fitch joins 19 other state attorneys general in urging the administration to protect against Chinese efforts to introduce unsafe pharmaceutical ingredients into the U.S. market, citing recent violations of FDA safeguards for popul...
Antengene's ATG-201 Autoimmune Therapy Receives Australian Clinical Trial Approval
Biotech company Antengene has secured regulatory clearance in Australia to begin Phase I trials of ATG-201, a bispecific antibody targeting B cell-related autoimmune diseases, marking the therapy's expansion beyond China into international markets....
FDA Clears Orum Therapeutics to Begin Testing Novel Leukemia Drug ORM-1153
The FDA has authorized Orum Therapeutics to proceed with human trials of ORM-1153, a first-in-class degrader-antibody conjugate targeting acute myeloid leukemia and other blood cancers. The Phase 1 study is expected to launch by year-end 2026....